Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Low Dose Radiotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04827862Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2022
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-Hodgkin lymphoma (NHL), sponsored by Abramson Cancer Center. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04827862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827862.